Company Overview of Mimetogen Pharmaceuticals Inc.
Mimetogen Pharmaceuticals Inc., a biotechnology company, engages in designing and developing small molecule drugs to treat dry eye, glaucoma, age-related macular degeneration, keratoconus, and retinitis pigmentosa. The company’s products mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. It provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded in 2...
1000 de La Gauchetière Street West
Montreal, QC H3B 5H4
Founded in 2004
Key Executives for Mimetogen Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President of Finance
Senior Director - Drug Discovery
Senior Scientist - Medicinal Chemistry
Compensation as of Fiscal Year 2014.
Mimetogen Pharmaceuticals Inc. Key Developments
Mimetogen Pharmaceuticals Inc. Announces Topline Results of its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome
Sep 9 14
Mimetogen Pharmaceuticals Inc. announced positive top line data from its second clinical study (Study Designation MIM-725) with MIM-D3, its lead drug for the treatment of dry eye syndrome. The trial demonstrated significant improvements in both signs and symptoms with 1% MIM-D3 versus placebo, together with excellent safety, comfort and tolerability profiles. Mimetogen has completed its initial analysis of the data and met with the FDA in order to confirm the outstanding requirements for the remainder of the clinical development plan. The 403-patient study (ClinicalTrials.gov Identifier: NCT01960010) utilized Ora's Controlled Adverse Environment (CAE(SM)) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. In the study, MIM-D3 successfully demonstrated superiority over placebo in the pre-specified endpoints of both central and total corneal fluorescein staining (change from pre to post CAE) at week 8 (p = 0.0134 and p = 0.0500, respectively) as measured via the Ora Calibra(TM) Scale. MIM-D3 also significantly improved common vision-related function symptoms of dry eye disease as measured via the OSDI(R) questionnaire. The mean blurred vision, reading and watching TV scores were lower in the MIM-D3 group than in the respective placebo groups at week 8 (p = 0.0393, p = 0.0433 and p = 0.0046, respectively). MIM-D3 was comfortable, well tolerated and there were no unexpected or serious ocular adverse events. The most commonly reported ocular adverse events were reduction of visual acuity (MIM-D3, 3%; Placebo, 3%); instillation site pain (MIM-D3 1%; placebo, 1.5%) and eye irritation (MIM-D3, 0%; Placebo, 1.5%). All adverse ocular events were mild and transient in nature.
Mimetogen Pharmaceuticals Inc. Announces Initiation of a Phase 3 Clinical Trial with MIM-D3 to Treat Dry Eye Syndrome
Oct 10 13
Mimetogen Pharmaceuticals Inc. announced that the initial patients have been enrolled in the company's first pivotal Phase 3 clinical study of MIM-D3 ophthalmic solution for the treatment of dry eye syndrome. MIM-D3 is the first in a class of molecules called TrkA agonists. MIM-D3 stimulates the production of mucin, which plays a critical role in the protection and overall health of the ocular surface. Mucins are essential for lubrication; the removal of allergen, pathogens, and debris; and corneal epithelial healing to reduce ocular surface damage. In addition, MIM-D3 may have additional benefits than currently available dry eye therapies, including the potential to improve neural function, which may improve corneal sensitivity and integrity. The pivotal trial will further evaluate the safety and efficacy of MIM-D3 in the treatment of dry eye syndrome. Approximately 400 patients will be randomized to receive 1% MIM-D3 ophthalmic solution or placebo twice daily over an 8 week period. The primary endpoints of the study are corneal fluorescein staining score in the CAE(SM) and ocular dryness. The safety and comfort of MIM-D3 compared to placebo will also be evaluated.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries